CoChat
Sign Up
Cited by 5CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

CAR T cell therapy efficacious against B-ALL across age groups

Sidaway, Peter·2018·Nature Reviews Clinical Oncology
DOI 10.1038/nrclinonc.2018.32
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2018.32

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CAR-T cell therapy shows high response rates to B-ALL patients in different age groups.

    “It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”

    From Immunosenescence: a key player in cancer development (2020) · cites this paper as [117]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Sidaway, P.
Corresponding author
Sidaway, Peter
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2018-02-20
Volume
15
Issue
4
Pages
199-199
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
DOI
10.1038/nrclinonc.2018.32
OpenAlex
W2788141413
Cited by
5
References
2
Citations by year
2026: 1 · 2023: 1 · 2021: 2 · 2020: 1
FWCI
0.28
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CAR T-cell therapy, B-cell acute lymphoblastic leukemia, tisagenlecleucel, CD19, pediatric and young adult patients, age groups, long-term follow-up, treatment efficacy
MeSH terms
B-Lymphocytes, Child, Humans, Immunotherapy, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review